Login / Signup

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices.

Nick BansbackJeffrey R CurtisJie HuangZeling HeMichael EvansTracy JohanssonKaleb D MichaudGabriela SchmajukKatherine P Liao
Published in: ACR open rheumatology (2020)
The uptake of biosimilars in the United States remains low despite persistence on infliximab-dyyb being similar to the infliximab bio-originator. These results add to clinical studies that should provide greater confidence to patients and physicians regarding biosimilar use.
Keyphrases
  • primary care
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • healthcare
  • rheumatoid arthritis
  • peritoneal dialysis
  • prognostic factors